Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a report published on Thursday. The brokerage issued a sell rating on the stock.

Separately, Roth Mkm reaffirmed a buy rating and issued a $40.00 price target on shares of Bio-Path in a research note on Thursday, April 18th.

Bio-Path Stock Performance

Shares of BPTH stock opened at $2.61 on Thursday. The firm’s 50 day moving average price is $4.26 and its two-hundred day moving average price is $8.06. Bio-Path has a 52-week low of $2.35 and a 52-week high of $44.80. The stock has a market cap of $1.77 million, a PE ratio of -0.06 and a beta of 0.45.

Bio-Path (NASDAQ:BPTH) last posted its quarterly earnings results on Friday, March 8th. The company reported ($5.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($5.40). During the same period in the prior year, the business earned ($10.60) earnings per share. As a group, sell-side analysts predict that Bio-Path will post -18.71 earnings per share for the current fiscal year.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.